DEBI Foundation

Debiopharm is a Swiss-based biopharmaceutical group that specializes in the development and manufacturing of innovative therapies for oncology and infectious diseases. The company operates a unique "search and development" business model, where it in-licenses promising drug candidates from academic and biotech partners, manages their clinical development, and then out-licenses them to global pharmaceutical companies for commercialization. Debiopharm's most successful developments include oxaliplatin (Eloxatin) and triptorelin (Trelstar), which are standard treatments in cancer care. Their current lead asset is xevinapant (Debio 1143), a first-in-class IAP antagonist in Phase 3 trials for head and neck cancer, licensed to Merck KGaA. The group also includes a dedicated manufacturing facility in Martigny, Switzerland, and an innovation fund that invests in digital health and smart data startups.